Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Common Equity (2019 - 2025)

Korro Bio (KRRO) has disclosed Common Equity for 6 consecutive years, with $99.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 44.87% year-over-year to $99.0 million, compared with a TTM value of $99.0 million through Sep 2025, down 44.87%, and an annual FY2024 reading of $160.4 million, down 5.59% over the prior year.
  • Common Equity was $99.0 million for Q3 2025 at Korro Bio, down from $115.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $198.1 million in Q2 2024 and bottomed at -$153.3 million in Q3 2023.
  • Average Common Equity over 5 years is $76.1 million, with a median of $115.1 million recorded in 2025.
  • Peak annual rise in Common Equity hit 271.57% in 2023, while the deepest fall reached 286.96% in 2023.
  • Year by year, Common Equity stood at -$42.2 million in 2021, then tumbled by 134.63% to -$99.0 million in 2022, then surged by 271.57% to $169.9 million in 2023, then dropped by 5.59% to $160.4 million in 2024, then plummeted by 38.27% to $99.0 million in 2025.
  • Business Quant data shows Common Equity for KRRO at $99.0 million in Q3 2025, $115.1 million in Q2 2025, and $139.0 million in Q1 2025.